title: Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma.
abstract: OBJECTIVE
  Recent studies have shown that the high affinity of mesothelin-CA125 interaction might cause intracavitary tumor metastasis. We examined the clinicopathologic significance and prognostic implication of mesothelin and CA125 expression in pancreatic ductal adenocarcinoma.
  
  
  METHODS
  Tissue samples from 66 pancreatic ductal adenocarcinomas were immunohistochemically examined. Proportion and intensity of constituent tumor cells with mesothelin and CA125 expression were analyzed and classified as high-level expression, defined as expression by more than 50% of tumor cells and/or moderate to strong staining, or low-level expression otherwise.
  
  
  RESULTS
  A high level of mesothelin was correlated with a higher histological grade (P = 0.049) and the level of blood vessel permeation (P = 0.0006), whereas a high level of CA125 expression was correlated with a higher recurrence rate (P = 0.015). The expression of mesothelin was strongly correlated with that of CA125 (P = 0.0041). Co-expression of mesothelin and CA125 were associated with an unfavorable patient outcome (P = 0.0062).
  
  
  CONCLUSIONS
  This is the first report showing that co-expression of mesothelin and CA125 were in pancreatic ductal adenocarcinoma, and such co-expression is associated with a poor prognosis. Our finding suggests that co-expression of these two factors plays a significant role in the acquisition of aggressive clinical behavior.
authors.affiliation: Department of General Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan. titiuehahaue@hotmail.com
authors.forename: Takahiro
authors.initials: T
authors.lastname: Einama
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Kamachi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nishihara
authors.forename: Shigenori
authors.initials: S
authors.lastname: Homma
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kanno
authors.forename: Kenta
authors.initials: K
authors.lastname: Takahashi
authors.forename: Ayami
authors.initials: A
authors.lastname: Sasaki
authors.forename: Munenori
authors.initials: M
authors.lastname: Tahara
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Okada
authors.forename: Shunji
authors.initials: S
authors.lastname: Muraoka
authors.forename: Toshiya
authors.initials: T
authors.lastname: Kamiyama
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Matsuno
authors.forename: Michitaka
authors.initials: M
authors.lastname: Ozaki
authors.forename: Satoru
authors.initials: S
authors.lastname: Todo
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology; D000368:Aged; D018394:CA-125 Antigen / Q000096:biosynthesis*; D021441:Carcinoma, Pancreatic Ductal / Q000378:metabolism* / Q000473:pathology; D005260:Female; D058851:GPI-Linked Proteins / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D000090204:Mesothelin; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D018394:CA-125 Antigen; D058851:GPI-Linked Proteins; D000090204:Mesothelin